![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLA1A |
Gene summary for PLA1A |
![]() |
Gene information | Species | Human | Gene symbol | PLA1A | Gene ID | 51365 |
Gene name | phospholipase A1 member A | |
Gene Alias | PS-PLA1 | |
Cytomap | 3q13.33 | |
Gene Type | protein-coding | GO ID | GO:0006575 | UniProtAcc | Q53H76 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51365 | PLA1A | HCC1_Meng | Human | Liver | HCC | 5.93e-55 | 2.07e-01 | 0.0246 |
51365 | PLA1A | HCC2 | Human | Liver | HCC | 1.85e-25 | 4.51e+00 | 0.5341 |
51365 | PLA1A | S014 | Human | Liver | HCC | 1.93e-03 | 2.55e-01 | 0.2254 |
51365 | PLA1A | S016 | Human | Liver | HCC | 4.17e-03 | 3.28e-01 | 0.2243 |
51365 | PLA1A | S027 | Human | Liver | HCC | 4.34e-05 | 7.78e-01 | 0.2446 |
51365 | PLA1A | S028 | Human | Liver | HCC | 5.39e-33 | 1.21e+00 | 0.2503 |
51365 | PLA1A | S029 | Human | Liver | HCC | 6.67e-40 | 1.82e+00 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000657521 | Liver | HCC | cellular modified amino acid metabolic process | 119/7958 | 188/18723 | 6.47e-09 | 1.67e-07 | 119 |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
GO:001604221 | Liver | HCC | lipid catabolic process | 175/7958 | 320/18723 | 6.50e-06 | 7.88e-05 | 175 |
GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLA1A | insertion | Frame_Shift_Ins | novel | c.399_400insA | p.Asn135LysfsTer4 | p.N135Kfs*4 | Q53H76 | protein_coding | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | ||
PLA1A | SNV | Missense_Mutation | novel | c.545N>T | p.Gln182Leu | p.Q182L | Q53H76 | protein_coding | tolerated(0.06) | benign(0.255) | TCGA-G3-AAV3-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLA1A | SNV | Missense_Mutation | novel | c.1043A>T | p.Lys348Met | p.K348M | Q53H76 | protein_coding | deleterious(0.02) | benign(0.275) | TCGA-05-4420-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PLA1A | SNV | Missense_Mutation | c.328N>A | p.Arg110Ser | p.R110S | Q53H76 | protein_coding | tolerated(0.06) | benign(0.058) | TCGA-55-7570-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PLA1A | SNV | Missense_Mutation | c.1244N>C | p.Ile415Thr | p.I415T | Q53H76 | protein_coding | deleterious(0.03) | benign(0.154) | TCGA-69-7978-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PLA1A | SNV | Missense_Mutation | novel | c.786N>T | p.Arg262Ser | p.R262S | Q53H76 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
PLA1A | SNV | Missense_Mutation | c.778N>T | p.His260Tyr | p.H260Y | Q53H76 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
PLA1A | SNV | Missense_Mutation | novel | c.98N>A | p.Pro33Gln | p.P33Q | Q53H76 | protein_coding | tolerated(0.47) | benign(0.023) | TCGA-22-5483-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | taxol | PD |
PLA1A | SNV | Missense_Mutation | c.1250N>A | p.Gly417Glu | p.G417E | Q53H76 | protein_coding | tolerated(0.06) | possibly_damaging(0.617) | TCGA-34-5240-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR | |
PLA1A | SNV | Missense_Mutation | rs769137788 | c.155A>C | p.Gln52Pro | p.Q52P | Q53H76 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-37-4135-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |